Malgorzata Kluba has been a Senior Biotechnology Analyst at Candriam since 2019.
Before joining Candriam Malgorzata spent four years as an R&D scientist at ActoBio Therapeutics (Intrexon Actobiotics) in Belgium – a synthetic biology company where she had been working on novel drug delivery platform. She has also worked as a journalist for a life sciences communication agency (BioVox / Tunstone Communications), focusing on Belgian biotechnology market.
Malgorzata holds PhD degree in biochemistry and biotechnology from University of Leuven, Belgium, where she researched cancer signalling pathways.
Discover the latest articles by Malgorzata Kluba, PhD
Malgorzata Kluba, Rudi Van den Eynde, Oncology, Equities
Preferiremmo che fosse un giorno come un altro, perché questo significherebbe che il cancro è stato sconfitto e che è curabile.